This article appeared in Fierce Biotech, March 2 2022
Category: Articles
Epsilogen’s CEO speaks to Lu Rahman about their ongoing work in developing novel IgE antibodies to treat cancer.
This article first appeared in Drug Discovery World, Spring 2021, Volume 22, Issue 2.
BioCentury
Epsilogen: co-opting IgE antibodies against cancer
Epsilogen Ltd was profiled in BioCentury’s Emerging Company Profile on June 5, 2020.
IGEM Therapeutics: Pursuing Novel IgE Antibodies For Solid Tumors
Emerging Company Profile: IGEM Therapeutics has been spun out of King’s College London to evaluate the use of IgE-based monoclonal antibodies for the treatment of cancer, including difficult-to-reach solid tumors….
…..
See the article in full here: https://scrip.pharmaintelligence.informa.com/SC123214/IGEM-Therapeutics-Pursuing-Novel-IgE-Antibodies-For-Solid-Tumors
Genetic Engineering News Article
Not to be Sneezed At
One of the stand-out technologies discussed by London-based immuno-oncology start-up Epsilogen was in antibody therapeutics…..
See the article in full here: https://www.genengnews.com/gen-exclusives/biotrinity-conference-focuses-on-nextgen-healthcare/77901102